Ultragenyx (RARE) Q2 2026 earnings review
Record Revenue Meets Massive H2 Execution Risk
Ultragenyx posted its highest quarterly revenue ever at $214 million (+28% YoY), shrugging off the seasonal dip seen in Q1. Operating leverage is finally materializing: combined R&D and SG&A expenses were held flat year-over-year, allowing the net loss to narrow to $92 million. While the commercial base is stabilizing the P&L, this quarter is merely a preamble. The entire investment thesis now hinges on an unprecedented convergence of binary catalysts in the second half of 2026: two PDUFA dates for novel gene therapies (DTX401 and UX111) and a pivotal Phase 3 readout for GTX-102 in Angelman syndrome. Management's promise of 2027 profitability relies entirely on flawless execution through this regulatory gauntlet.
🐂 Bull Case
The company generated 28% top-line growth while keeping total operating expenses at $289M (vs $275M YoY), with R&D and SG&A basically flat. This operating leverage proves their 2027 profitability framework is mathematically sound.
Approval of DTX401 (August) and UX111 (September), combined with a potential positive Phase 3 Aspire readout (Sept/Oct) for GTX-102, would rapidly shift the company into a multi-franchise rare disease powerhouse.
🐻 Bear Case
The 2027 profitability target relies heavily on monetizing two Priority Review Vouchers (PRVs) estimated at >$100M each. If either gene therapy receives a Complete Response Letter (CRL), the PRV cash vanishes, and the profitability timeline collapses.
Despite a narrowing loss, operating cash outflow was $97 million in Q2. With the cash balance down to $436 million, a failure in the H2 catalysts would almost certainly force a highly dilutive capital raise.
⚖️ Verdict: ⚪
Neutral. The commercial execution is excellent and cost control is working. However, the sheer density of binary regulatory and clinical risk clustered in August-October 2026 makes this a highly speculative holding in the near term.
Key Themes
Commercial Engine Firing on All Cylinders
The base business is performing exceptionally well. Crysvita hit a record $156 million in Q2, rebounding powerfully from Q1. Evkeeza revenue accelerated to $21 million (up 50% YoY from $14M in 25Q2), driven by ex-US traction and early access programs. This steady double-digit growth provides the baseline cash flow needed to support the upcoming gene therapy launches.
Cost Containment Delivers Real Leverage
Following late 2025's 10% workforce reduction, the structural changes to the P&L are visible. Q2 2026 R&D expenses were $167M (vs $165M in 25Q2) and SG&A was $88M (vs $87M in 25Q2). Generating $47M in incremental YoY revenue without increasing core OpEx is the clearest signal yet that management is serious about GAAP profitability in 2027.
Execution Risk on the 'H2 Catalyst Trifecta'
The company faces an unprecedented sequence of events: PDUFA for DTX401 (August 23), PDUFA for UX111 (September 19), and pivotal Phase 3 data for GTX-102 (September/October). While DTX401 and UX111 are de-risked by prior FDA interactions, gene therapy manufacturing reviews remain notoriously stringent. A delay or CRL on any of these would severely damage the growth narrative.
Macro Impact: Brazil's Ministry of Health Distorting Quarter-to-Quarter Results
Crysvita's revenue trajectory remains highly volatile ($145M in 25Q4 -> $93M in 26Q1 -> $156M in 26Q2). This 'sawtooth' pattern is directly tied to uneven, bulk ordering practices by the Brazilian Ministry of Health. While annual totals align with guidance, this lumpiness obscures underlying global demand trends and makes quarterly earnings heavily dependent on Latin American government bureaucracy.
Cash Position Contradicts 'Fully Funded' Narrative
Management insists they are fully funded to profitability, but the balance sheet raises questions. Total cash sits at $436 million, down from $737 million at the end of 2025. With a Q2 operating cash burn of $97 million, they have roughly 4-5 quarters of runway. The 2027 profitability model explicitly relies on selling two PRVs (estimated >$100M each). If the gene therapies fail to secure approval, those PRVs vanish, and severe dilution becomes unavoidable.
GTX-102 (Angelman Syndrome) as the Ultimate Value Driver
The Phase 3 Aspire study for the antisense oligonucleotide GTX-102 is the company's highest-upside asset. Prior Phase 1/2 data showed a ~10-point mean change from baseline on the Bayley-4 cognitive score, significantly exceeding the 6-point meaningful difference. With data expected in September or October, a decisive win on the co-primary endpoints (Bayley-4 and MDRI) would open a massive commercial market.
Other KPIs
A sequential improvement from Q1's $(197) million burn (which was impacted by annual bonuses and UX143 manufacturing prep). However, a continuous ~$100M quarterly burn rate highlights the necessity of the upcoming gene therapy approvals to monetize PRVs and bridge the gap to 2027 profitability.
Accelerating. Up 50% from $14 million in 25Q2, driven by new country launches and early access adoption ex-US. Evkeeza is quietly becoming a meaningful contributor to the top line, validating the company's global commercial infrastructure.
Guidance
Stable. Reaffirmed guidance implies 8-13% YoY growth compared to FY25 ($673M). Crucially, this guidance completely excludes any potential revenue from the upcoming DTX401 or UX111 product launches in late 2026.
Stable. Reaffirmed. Implies 4-8% growth over FY25's $481M. The massive $156M Q2 result covers 30% of the high-end of this guidance, compensating for the weak Q1.
Stable. Reaffirmed. Implies 4-14% growth over FY25's $96M. A recent launch in Japan (May 2026) following NHI listing should help secure the upper half of this range.
Stable. Reaffirmed. Management is executing perfectly against this metric so far. They also reaffirmed the bolder 2027 target: reducing combined OpEx by at least 15% versus 2025.
Key Questions
PRV Monetization Timeline
Your path to profitability assumes the sale of two PRVs. Given the tight timeline between the August/September PDUFA dates and your cash runway, how quickly do you anticipate being able to monetize these vouchers in the current market environment?
Gene Therapy Commercial Launch Logistics
With DTX401 and UX111 potentially being approved within four weeks of each other, how is the commercial team prioritizing payer negotiations and site onboarding to prevent launch bottlenecks?
GTX-102 Endpoint Dynamics
For the upcoming Phase 3 Aspire data in Angelman syndrome, if the Multi-Domain Responder Index (MDRI) is highly statistically significant but the Bayley-4 cognitive score barely misses its alpha allocation, do you believe that profile is still fileable for approval?